HIV infection and hepatitis B seroprevalence among antenatal clinic attendees in Niger, West Africa
Saïdou Mamadou1,2, Moussa Ide3, Amadou Roufaï Ali Maazou2, Balki Aoula2, Seyni Labo4, Mamane Bozari4
1Laboratory of Bacteriology-Virology, Faculty of Health Sciences, University Abdou Moumouni, Niamey, Niger; 2National Reference Laboratory for STI/HIV/TB, Niamey, Niger; 3Coordination Board, Inter-Sectorial Program on STI/HIV/AIDS, Niamey, Niger; 4National Center for Social Sciences Expertise, Niamey, Niger
Abstract: This transversal study was suggested in order to estimate the nationwide seroprevalences of HIV infection and hepatitis B among 495 pregnant women in Niger in 2008. The study detected anti-HIV antibodies with Genscreen® Plus HIV Ag/Ab Ultra Kit (Bio-Rad; Hercules, CA), Vironostika® HIV Uni-Form II Ag/Ab (bioMérieux; Marcy-l’Etoile, France), and ImmunoComb® II HIV 1 and 2 BiSpot (Orgenics; Yavne, Israel). HBsAg was detected by Monolisa® HBsAg Ultra (Bio-Rad) and ImmunoComb® II HBsAg (Orgenics). The rates obtained were 2.02% (95% confidence intervals (CI): 1.03%–3.81%) and 16.16% (95% CI: 13.09%–19.77%), respectively. There were no significant variations according to environment, region, age, marital status, educational level, antecedent of surgery and transfusion. But these data need a large sample, and periodic updates for a better planning of activities in the framework of a national reproductive health program, including prevention of mother-to-child HIV transmission.
Keywords: HIV, HBV, seroprevalence, pregnant women, Niger
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]